IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.
ETOP 14-18 CHESS
Phase 2 small_molecule active
Quick answer
IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion. for NSCLC, synchronous oligo-metastatic is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Partner Therapeutics Limited
- Indication
- NSCLC, synchronous oligo-metastatic
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active